President Donald Trump is ramping up the heat on pharmaceutical companies, urging them in letters sent Thursday to cut down drug prices in accordance with an executive order he signed in May.
But Trump has limited authority to actually force drug companies to adjust prices, according to experts, and his effort equates to price control.
As a result, utilizing public pressure through these letters may be one tool he’s employing to get companies to comply, according to Benedic Ippolito, a senior fellow in economic policy studies at the conservative-leaning American Enterprise Institute think tank.
"One of the big questions has been just how much can the administration realistically pressure these drugmakers to do something that is at least nominally voluntary," Ippolito told Fox News Digital Monday.